<DOC>
	<DOC>NCT01922271</DOC>
	<brief_summary>The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and specific airway resistance in patients with moderate to severe COPD.</brief_summary>
	<brief_title>Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male or female adults aged ≥40 years Patients with moderate to severe COPD defined by a postbronchodilator Forced Expiratory Volume in One Second (FEV1)/(FVC) Forced Vital Capacity ratio of &lt;0.70 and a postbronchodilator FEV1 of ≤70% and FEV1 ≥ 30% of predicted normal values. Current or exsmokers who have a smoking history of at least 10 pack years. Pregnant or nursing (lactating) women Patients who have a clinically significant laboratory abnormality at runin Patients with narrowangle glaucoma, symptomatic benign prostatic hyperplasia or bladderneck obstruction or moderate to severe renal impairment (GFR &lt;50 ml/min/1,732) or urinary retention. (BPH patients who are stable on treatment can be considered). Patients with any history of asthma Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation Patients receiving medications in the classes listed in the protocol as prohibited. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>COPD</keyword>
</DOC>